Apomorphine Nasal Powder in the Treatment of Parkinson's Disease "Off" Periods.

To determine the safety and tolerability of repeated dosing with Apomorphine Nasal Powder in subjects with Parkinson's Disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

1 year history of Parkinson's Disease; stable PD medications for 4 weeks; at least one documented "off" period per day

Exclusion criteria

hypersensitivity to apomorphine; participation in a clinical trial in the last 12 weeks; pregnant or lactating females

Treatment and study plan

Apomorphine Nasal Powder

Drug

Sponsors and collaborators

Lead sponsor

Britannia Pharmaceuticals Ltd.

Industry

Registry information

Important dates

Study start: 2006
Primary completion: 2007
Study completion: 2007
First posted: Jun 30, 2006
Registry last updated: Jul 10, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed